⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APVO News
Aptevo Therapeutics Inc
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
accessnewswire.com
APVO
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
accessnewswire.com
APVO
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
accessnewswire.com
APVO
APVO
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
accessnewswire.com
APVO
APVO
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
accessnewswire.com
FMST
APVO
FMST
APVO
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
accessnewswire.com
APVO
APVO